加载中
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
收盘时
US$0.9472
−US$0.0083 · -0.87%
盘中时间采用ET。市场数据可能有所延迟。
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
日内区间
当前US$0.9472
52周区间
当前US$0.9472
盘中时间采用ET。市场数据可能有所延迟。
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
日内区间
当前US$0.9472
52周区间
当前US$0.9472
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 441.3万 USD | 405.5万 USD | 603.6万 USD | 248.8万 USD | — |
| 销货成本 | 238.9万 USD | 196.8万 USD | 70.4万 USD | — | — |
| 毛利 | 202.4万 USD | 208.7万 USD | 533.2万 USD | 248.8万 USD | — |
| 研究与开发 | 3975万 USD | 3212.6万 USD | 3957.3万 USD | 5615.9万 USD | 3510.8万 USD |
| 销售、一般及管理费用 | 2757.9万 USD | 2668.6万 USD | 3199.4万 USD | 3540万 USD | 2292万 USD |
| 营业费用 | 6494万 USD | 5684.4万 USD | 7086.3万 USD | 9155.9万 USD | 5802.8万 USD |
| 利息收入 | 92.2万 USD | 130万 USD | 250万 USD | 140万 USD | — |
| 利息支出 | 518.8万 USD | — | — | — | 7.9万 USD |
| 折旧和摊销 | 238.9万 USD | 196.8万 USD | 70.4万 USD | 48万 USD | 22.9万 USD |
| 营业利润 | −6291.6万 USD | −5475.7万 USD | −6553.1万 USD | −8907.1万 USD | −5802.8万 USD |
| 净利润 | −6784.6万 USD | −5405.4万 USD | −6307.8万 USD | −8680.4万 USD | −5836.5万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$5.00
上涨空间 427.87%价格历史记录不可用
最高：US$6.00平均的：US$5.00最低：US$3.50报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1353.55万0.00%2.3万亿 USD0.03%US$381.57-0.10%
State Street SPDR S&P Biotech ETFXBI1018.81万0.10%98.74亿 USD0.35%US$151.4-1.54%
iShares Russell 2000 ETFIWM863.23万0.01%787.4亿 USD0.19%US$277.88-0.38%
Vanguard Extended Market ETFVXF523.02万0.01%954亿 USD0.05%US$233.52-0.63%
Vanguard Russell 2000 ETFVTWO261.26万0.01%180亿 USD0.06%US$112.27-0.35%
iShares Russell 2000 Growth ETFIWO210.34万0.02%139.17亿 USD0.24%US$353.71-0.86%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP171.52万0.07%26.06亿 USD0.20%US$65.26-1.64%
Vanguard Health Care ETFVHT132.89万0.01%220亿 USD0.09%US$320.67+0.52%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOState Street SPDR S&P Kensho New Economies Composite ETFKOMPVanguard Health Care ETFVHTAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
